Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00200434 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension
A Phase 3 study, sponsored by Mylan Bertek Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT00200434: Completed Phase 3 study, sponsored by Mylan Bertek Pharmaceuticals.
NCT00200434 is a Phase 3 study that has completed, run by Mylan Bertek Pharmaceuticals. The registered enrollment target is 600 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00200434, a Phase 3 study, has completed, sponsored by Mylan Bertek Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
The purpose of this study was to contrast the efficacy and safety of 3 dose levels of nebivolol vs. placebo, when added to a patient's existing antihypertensive medication(s) for 3 months, in patients with mild to moderate hypertension
Interventions
- DRUG Nebivolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2002-10 |
| Est. Completion | 2003-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00200434
The ClinicalTrials.gov registry entry for NCT00200434 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Bertek Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nebivolol is the first listed.
NCT00200434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00200434 about?
NCT00200434 is a clinical study titled "A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension". The purpose of this study was to contrast the efficacy and safety of 3 dose levels of nebivolol vs. placebo, when added to a patient's existing antihypertensive medication(s) for 3 months, in patients with mild to moderate hypertension
What is the current status of trial NCT00200434?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2002-10. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00200434?
The interventions under investigation include: Nebivolol (DRUG).
Who is sponsoring clinical trial NCT00200434?
This trial is sponsored by Mylan Bertek Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.